Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.

ABSTRACT: Pemphigus vulgaris is an autoimmune blistering disease characterized by autoantibodies that target desmoglein adhesion proteins. Rituximab and corticosteroids are Food and Drug Administration‒approved therapies for pemphigus vulgaris. As newer treatments for pemphigus enter clinical trials, analysis of clinical and serologic outcomes after rituximab therapy as a function of time is essential to guide clinical trial design. In this study, we report detailed temporal and serologic outcomes of rituximab treatment of pemphigus vulgaris. The maximal prevalence of complete remission off oral systemic therapy after a single cycle of rituximab was 32.4% at 12 months or 43.1% by 36 months, including additional rituximab cycles. Using receiver operating characteristic curves to develop prediction mo

SUBMITTER: Tovanabutra N 

PROVIDER: S-EPMC8957519 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature